Clinical Trial

A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN069 in Chinese male participants with Obesity or Overweight.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-06; most recent amendment 2025-09-16.
Status change: Not Yet Recruiting → Recruiting 2024-09-03
Trial Details
NCT Number NCT06547775
Lead Sponsor Suzhou Alphamab Co., Ltd.
Conditions Overweight or Obesity
Enrollment 36 participants
Start Date 2024-08-02
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-17